Phenotypic characterization and distribution of dendritic cells in parotid gland tumors

ORL

Volumn 66, Issue 6, 2004, Pages 313-319

  Wischatta, Martin ^a   Brunhuber, Thomas ^a   Neher, Andreas ^a   Kacani, Laco ^a   Romani, Nikolaus ^b   Schrott Fischer, Annelies ^a   Sprinzl, Georg Mathias ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b Universitatsklinik fuer Dermatologie und Venerologie Innsbruck   (Austria)

Author keywords

Adenomas; Carcinomas; Dendritic cells; Langerhans cells; Parotid gland

Indexed keywords

ADULT; AGED; ARTICLE; CELL DENSITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; MALE; PAROTID GLAND CANCER; PAROTID GLAND TUMOR; PHENOTYPE; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, SURFACE; CARCINOMA, SQUAMOUS CELL; DENDRITIC CELLS; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; LECTINS, C-TYPE; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MALE; MANNOSE-BINDING LECTINS; MIDDLE AGED; PAROTID NEOPLASMS; PHENOTYPE; PROGNOSIS;

EID: 13244292574     PISSN: 03011569     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081888     Document Type: Article

References (30)

1. Caux C, Dezutter-Dambuyant C, Schmitt D, et al: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258-261.
2. Lukas M, Stossel H, Hefel L, et al: Human cutaneous dendritic cells migrate through dermal lymphatic vessels in a skin organ culture model. J Invest Dermatol 1996;106:1293-1299.
3. Wollenberg A, Mommaas M, Oppel T, et al: Expression and function of the mannose receptor CD206 on epidermal dendritic cells in inflammatory skin diseases. J Invest Dermatol 2002;118:327-334.
4. Pope M, Elmore D, Ho D, et al: Dendrite cell-T cell mixtures, isolated from the skin and mucosae of macaques, support the replication of SIV. AIDS Res Hum Retro 1997;13:819-827.
5. Sprinzl GM, Hussl B, Obrist P, et al: Dendritic cells in precancerous lesions of the larynx. Laryngoscope 2000;110:13-18.
6. Maluccio MA, Rao J, Sharma V, et al: Dendritic cells armed with anti-CD3 mAbs reduce pulmonary metastases, prolong survival, and engender antitumor effector cells demonstrable by adoptive transfer. Ann Surg Oncol 2000;7:771-776.
7. Giovarelli M, Cappello P, Forni G, et al: Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol 2000;164:3200-3206.
8. Wischatta M, Sprinzl GM, Gunkel AR, et al: Dendritic cells in selected head and neck tumors. Ann Otol Rhinol Laryngol 2000;109:56-62.
9. Romani N, Ratzinger G, Pfaller K, et al: Migration of dendritic cells into lymphatics - the Langerhans cell example: Routes, regulation, and relevance. Int Rev Cytol 2001;207:237-270.
10. Saint-Vis B, Vincent J, Vandenabeele S, et al: A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 1998;9:325-336.
11. Jaffe R, DeVaughn D, Langhoff E: Fascin and the differential diagnosis of childhood histiocytic lesions. Pediatr Dev Pathol 1998;1:216-221.
12. Valladeau J, Ravel O, Dezutter-Dambuyant C, et al: Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000;12:71-81.
13. Valladeau J, Duvert-Frances V, Pin JJ, et al: The monoclonal antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface. Eur J Immunol 1999;29:2695-2704.
14. Reichert TE, Scheuer C, Day R, et al: The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001;91:2136-2147.
15. Whiteside TL: Immunobiology and immunotherapy of head and neck cancer. Curr Oncol Rep 2001;3:46-55.
16. Goldman SA, Baker E, Weyant RJ, et al: Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 1998;124:641-646.
17. Ma Y, Xian M, Li J, et al: Interrelations of clinicopathological variables, local immune response and prognosis in esophageal squamous cell carcinoma. APMIS 1999;107:514-522.
18. Sobin LH, Wittekind C (eds): UICC TNM Classification of Malignant Tumours, ed 6. New York, Wiley-Liss, 2002.
19. Beckhardt RN, Weber RS, Zane R, et al: Minor salivary gland tumors of the palate: Clinical and pathologic correlates of outcome. Laryngoscope 1995;105:1155-1160.
20. Spiro RH: Management of malignant tumors of the salivary glands. Oncology (Huntingt) 1998;12:671-680; discussion 683.
21. Geijtenbeek TB, Torensma R, van Vliet SJ, et al: Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000;100:575-585.
22. Dieu-Nosjean MC, Massacrier C, Homey B, et al: Macrophage inflammatory protein 3α is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000;192:705-718.
23. Charbonnier AS, Kohrgruber N, Kriehuber E, et al: Macrophage inflammatory protein 3 alpha is involved in the constitutive trafficking of epidermal Langerhans cells. J Exp Med 1999;190:1755-1768.
24. Steinman RM, Dhodapkar M: Active immunization against cancer with dendritic cells: The near future. Int J Cancer 2001;94:459-473.
25. Banchereau J, Schuler-Thurner B, Palucka AK, et al: Dendritic cells as vectors for therapy. Cell 2001;106:271-274.
26. Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138-147.
27. Sadanaga N, Nagashima H, Mashino K, et al: Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001;7:2277-2284.
28. Kobayashi T, Shinohara H, Toyoda M, et al: Regression of lymph node metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: Report of a case. Surg Today 2001;31:513-516.
29. Chi KH, Myers JN, Chow KC, et al: Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology 2001;60:110-115.
30. Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-1678.